Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Coronavirus
Biotech Response to COVID-19

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and cures to protect individuals from contracting the virus.

Blog Posts
Vaccine
April 12, 2021
The “I AM BIO” podcast returns with an important topic – how to address COVID-19 vaccine hesitancy. Full episode here: https://www.bio.org/podcast or on your favorite podcast platform including …
covid-19
March 11, 2021
One year ago today, the World Health Organization (WHO) declared COVID-19 a “pandemic.” Here’s a look back at key activities from BIO and the industry over the past year—and how we were able to come so far, so…
Ted Love
February 25, 2021
Mapillar Dahn has three daughters—and they all have sickle cell disease. But she gained hope thanks to Global Blood Therapeutics (GBT) drug Oxbryta, the first FDA-approved drug targeting the underlying cause of sickle…
Press Releases
March 18, 2021
The Biotechnology Innovation Organization (BIO) welcomes the confirmations this week of Katherine Tai to the position of U.S. Trade Representative (USTR) and Xavier Becerra to lead the Department of Health and Human Services (HHS).  The United States leads the world in biotechnology…
March 10, 2021
Today, Congress passed the “American Rescue Plan” – a $1.9 trillion coronavirus relief package aimed at alleviating some of the economic and health impacts of the COVID-19 pandemic. Upon passage of the bill, Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation…
January 27, 2021
As Congress and the new President lay out their aggressive “100 Day Plans,” The Biotechnology Innovation Organization (BIO) today released a new blueprint highlighting goals to strengthen America’s innovation ecosystem, end the COVID-19 pandemic, and get more Americans back to work over the first…
Letters, Comments & Testimony
April 6, 2021
On Tuesday, April 6th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s January 2021 draft industry guidance on “Human Gene Therapy for Neurodegenerative Diseases.” In its comments, BIO stated that while the guidance covers many critical development issues for gene therapies,…
March 26, 2021
On Friday, March 26th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s public meeting announcement titled, “Best Practices for Development and Application of Disease Progression Models.” BIO appreciates that FDA is seeking input from stakeholders on three key areas,…
December 23, 2020
On Wednesday, December 23rd, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s October 2020 public workshop titled, “New Drugs Regulatory Program Modernization: Implementation of the Integrated Assessment of Marketing Applications and Integrated Review Documentation.” In its…
Patient-Take-Action
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.